Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that TP53 deletion status confers therapeutic sensitivity to Venetoclax in patients with Chronic Lymphocytic Leukemia.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.